Definium Therapeutics, Inc. 4

CFO Brandi Roberts received 62,500 Definium Therapeutics common shares via vesting of performance share units as part of an equity award.

On August 12, 2026, Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc., reported an acquisition of 62,500 common shares at a stated price of $0.00 per share, corresponding to the second tranche of performance share units originally granted effective June 2, 2025. These shares are part of a performance-based equity award that remains subject to vesting conditions tied to continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones. Following this award-related acquisition, Roberts' directly held ownership increased to 271,987 common shares, further aligning her compensation with the company’s long-term performance.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-345835

Alert Tier

5